Abstract 20P
Background
Biomarkers of response to IT are lacking in HGSC and PD-L1 expression failed to predict benefit in the randomized NeoPembrOv trial assessing peri-operative chemotherapy with or without pembrolizumab. We hypothesize that heterogeneity of samples site may impact the biomarker evaluation.
Methods
Biopsy of intra-abdominal metastases (M) or primary tubo-ovaries (TO) were obtained before any treatment. PD-L1 expression (Ventana SP263) (N = 85), multiplex immunofluorescence (mIF) (N = 64) and RNAseq data (N = 57) were assessed. Differentially expressed genes (DEG) and gene set enrichment analysis (GSEA) were obtained with DESeq2. Survival was analyzed with Cox models.
Results
No major difference of immune infiltration was seen between TO and M samples (mIF data). TO were enriched in tumor cells and TPS ≥ 1 samples (Table). In M, CPS ≥1 was predictive of better PFS in the pembrolizumab arm as compared to chemotherapy alone arm (HR interaction = 0.26 CI 95% 0.07-0.93 P = 0.034). No significant benefit was seen with TPS and IC, nor in TO. Intra-tumoral CD8 T cell (iCD8) density was higher in the IC, TPS and CPS ≥ 1 subgroups and was correlated with PD-L1 expression in M but not in TO (Table). Higher iCD8 T cells density (P = 0.03) and an enrichment of immune hallmarks (Interferon alpha and gamma, allograft rejection, inflammatory response, P < 0.05) was seen in CPS ≥ 1 M vs CPS ≥ 1 TO. On the other hand, CPS ≥ 1 TO samples were enriched in proliferative pathways (MYC and E2F target, G2M checkpoint, oxidative phosphorylation, P < 0.05) compared to CPS ≥ 1 M. Table: 20P
Tubo-ovary n=29 | Metastases, n=56 | P-value | |
PD-L1 expression | |||
Combined positive score (CPS) ≥ 1 | 79% | 60% | 0.08 |
Tumor positive score (TPS) ≥ 1 | 66% | 34% | 0.01 |
Immune cell score (IC) ≥ 1 | 45% | 53% | 0.48 |
Correlation between PD-L1 and iCD8 T cells (spearman ρ) | |||
CPS | ρ = 0.27 P = 0.2 | ρ = 0.53 P < 0.001 | |
TPS | ρ = 0.34 P = 0.1 | ρ = 0.50 P < 0.001 | |
IC | ρ = 0.02 P = 0.9 | ρ = 0.49 P < 0.001 |
Conclusions
CPS ≥ 1 in M, but not in primitive tumor, is associated with pembrolizumab benefit, consistent with the increase of iCD8 T cells in PD-L1 positive M. This indicates that the site of tumor sampling influence prediction of potential efficacy of PDL1 inhibitors in HGSC.
Clinical trial identification
NCT03275506.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Leheurteur: Financial Interests, Personal, Advisory Board: MSD. F. Selle: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, GSK/Tesaro, Eisai; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, GSK/Tesaro. C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Vertex, Seattle Genetics, Amgen, INC, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid, Puma; Financial Interests, Personal, Invited Speaker: Eisai, Prime oncology, Teva; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Institutional, Other, Internal speaker: Genentech; Financial Interests, Personal, Other, Regional speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, Adaptimmune, Eisai, SUTRO, BMS, Adaptimmune, Daiichi Sankyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Personal, Principal Investigator: PAOLA1; Non-Financial Interests, Personal, Other, President: GINECO. O. Le Saux: Financial Interests, Personal, Advisory Board: Novartis, MSD, GSK; Financial Interests, Personal, Invited Speaker: Lilly, AstraZeneca, Clovis; Financial Interests, Institutional, Trial Chair: Novartis, Hospira-Pfizer foundation, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display
35P - Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients
Presenter: Jani Sofia Almeida
Session: Poster Display